Herein, we have demonstrated that CAFs promoted ICC malignancy in vitro and in vivo, and nintedanib treatment suppressed the ability of CAFs to enhance the aggressiveness of ICC cells. This evidence concerns the gene TBX1 and intrahepatic cholangiocarcinoma.